Yanan Zhu
Stock Analyst at Wells Fargo
(1.03)
# 2,955
Out of 4,667 analysts
57
Total ratings
25%
Success rate
-10.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Overweight | $80 → $70 | $13.12 | +433.54% | 2 | Nov 18, 2024 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $17 → $4 | $1.07 | +273.83% | 4 | Nov 12, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $82 → $77 | $35.40 | +117.51% | 2 | Nov 7, 2024 | |
| EDIT Editas Medicine | Maintains: Overweight | $9 → $7 | $2.41 | +190.46% | 5 | Nov 5, 2024 | |
| BLUE bluebird bio | Maintains: Equal-Weight | $3 → $2 | $0.30 | +560.07% | 7 | Sep 25, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Overweight | $35 → $40 | $27.50 | +45.45% | 2 | May 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $70 → $65 | $47.26 | +37.54% | 1 | May 9, 2024 | |
| ENGN enGene Holdings | Initiates: Overweight | $30 | $7.50 | +300.00% | 1 | Apr 22, 2024 | |
| AFMD Affimed | Maintains: Overweight | $30 → $25 | $2.72 | +819.12% | 5 | Apr 1, 2024 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $45 → $58 | $16.17 | +258.69% | 5 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $1.71 | +1,361.99% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $25 | $8.14 | +207.13% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $43.65 | +14.55% | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $14 | $5.30 | +164.40% | 1 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $5 | $2.22 | +125.23% | 2 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $1.95 | +105.13% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.13 | +21,026.76% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $8 | $2.80 | +185.71% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $105 | $24.49 | +328.75% | 2 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $10 | $2.01 | +397.51% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1.5 → $3 | $0.66 | +351.33% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $34 → $24 | $5.70 | +321.05% | 1 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $591.82 | -44.92% | 1 | Feb 2, 2021 |
Intellia Therapeutics
Nov 18, 2024
Maintains: Overweight
Price Target: $80 → $70
Current: $13.12
Upside: +433.54%
RAPT Therapeutics
Nov 12, 2024
Maintains: Overweight
Price Target: $17 → $4
Current: $1.07
Upside: +273.83%
Ionis Pharmaceuticals
Nov 7, 2024
Maintains: Overweight
Price Target: $82 → $77
Current: $35.40
Upside: +117.51%
Editas Medicine
Nov 5, 2024
Maintains: Overweight
Price Target: $9 → $7
Current: $2.41
Upside: +190.46%
bluebird bio
Sep 25, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $0.30
Upside: +560.07%
Spyre Therapeutics
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $27.50
Upside: +45.45%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $47.26
Upside: +37.54%
enGene Holdings
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $7.50
Upside: +300.00%
Affimed
Apr 1, 2024
Maintains: Overweight
Price Target: $30 → $25
Current: $2.72
Upside: +819.12%
Arcturus Therapeutics Holdings
Mar 8, 2024
Maintains: Overweight
Price Target: $45 → $58
Current: $16.17
Upside: +258.69%
Mar 5, 2024
Initiates: Overweight
Price Target: $25
Current: $1.71
Upside: +1,361.99%
Mar 1, 2024
Maintains: Overweight
Price Target: $22 → $25
Current: $8.14
Upside: +207.13%
Jan 3, 2024
Reiterates: Overweight
Price Target: $50
Current: $43.65
Upside: +14.55%
Jan 2, 2024
Upgrades: Overweight
Price Target: $9 → $14
Current: $5.30
Upside: +164.40%
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $2.22
Upside: +125.23%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $1.95
Upside: +105.13%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $2.13
Upside: +21,026.76%
Mar 27, 2023
Assumes: Overweight
Price Target: $8
Current: $2.80
Upside: +185.71%
Mar 1, 2023
Maintains: Overweight
Price Target: $125 → $105
Current: $24.49
Upside: +328.75%
Jan 4, 2023
Maintains: Overweight
Price Target: $14 → $10
Current: $2.01
Upside: +397.51%
Nov 14, 2022
Maintains: Equal-Weight
Price Target: $1.5 → $3
Current: $0.66
Upside: +351.33%
Aug 9, 2022
Maintains: Equal-Weight
Price Target: $34 → $24
Current: $5.70
Upside: +321.05%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $591.82
Upside: -44.92%